Ars Pharma
San Diego, US · Founded 2015 · 4 known investors
ARS Pharma develops needle-free epinephrine treatments, including neffy, an FDA-approved epinephrine nasal spray for patients and caregivers managing allergic reactions. The company focuses on providing portable, easy-to-use alternatives to needle-based epinephrine delivery.
Founders & leadership
Ars Pharma was founded in 2015 by Richard Lowenthal.
RL
Richard LowenthalFounder
PS
Pratik ShahNamed on SEC filing
Board
JL
Jonathan LeffBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$63M disclosed across 2 rounds · 2018–2021
▶$55MraisedSep 2021 · 8 investors · PharmaceuticalsRule 506(b)
▶$55MraisedSep 2021 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rajeev DadooDirector
- Peter KolchinskyDirector
- Mike KellyDirector
- Brent SaundersDirector
- Richard LowenthalExecutive Officer, Director
- Dana McGowanExecutive Officer
- Pratik ShahDirector
- Jonathan LeffDirector
- Phil SchneiderDirector
- Offering amount
- $55M
- Amount sold
- $55M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedOct 2018 · 2 investors · PharmaceuticalsRule 506(b)
▶$8MraisedOct 2018 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan LeffDirector
- Richard LowenthalExecutive Officer, Director
- Pratik ShahDirector
- Offering amount
- $20M
- Amount sold
- $8M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
ARS Pharmaceuticals Q2 2026 revenue jumps, loss widens | SPRY Quarterly Report (10-Q)stocktitan.net · Aug 2026
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rightsbarchart.com · Aug 2026Frequently asked questions
- What does Ars Pharma do?
- ARS Pharma develops needle-free epinephrine treatments, including neffy, an FDA-approved epinephrine nasal spray for patients and caregivers managing allergic reactions. The company focuses on providing portable, easy-to-use alternatives to needle-based epinephrine delivery.
- Who founded Ars Pharma?
- Ars Pharma was founded by Richard Lowenthal in 2015.
- Who are Ars Pharma's investors?
- Ars Pharma's investors include Nextech Invest, OrbiMed, RA Capital, SR One Capital Management.
- How much funding has Ars Pharma raised?
- Ars Pharma has disclosed $63M raised across 2 rounds.
- Where is Ars Pharma headquartered?
- Ars Pharma is headquartered in San Diego, US.